UCB Cimzia Advances Pregnancy And Lactation Labeling For Biologics
Executive Summary
First industry-sponsored pharmacokinetic studies evaluating transfer of a biologic through placenta and breast milk support US FDA approval of new labeling describing low level of Cimzia in fetuses and infants – and highlight the pregnancy and lactation research challenges being explored by task force under 21st Century Cures Act.
You may also be interested in...
US FDA’s Higher Bar For Postmarketing Pregnancy Studies Shown By AMAG’s Vyleesi, Sprout’s Addyi
Agency’s postmarketing requirements to assess Vyleesi risk in pregnant and lactating women highlight the changes catalyzed by draft guidances issued in April.
UCB Buoyed By More Positive Bimekizumab Data
The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.
Interview: UCB Sees Bimekizumab As Good Long-Term Bet
UCB immunology chief Emmanuel Caeymaex tells Scrip that despite intense competition, the dual neutralization approach of bimekizumab in inhibiting both interleukin-17A and IL-17F could result in a treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis that may produce faster and more durable clinical improvements than the drugs already on the market.